Table 1 Baseline characteristics of patients in empagliflozin group and sitagliptin group
| Â | Empagliflozin | Sitagliptin | p value |
|---|---|---|---|
Age (years) | 52.8 ± 9.7 | 47.8 ± 11.5 | 0.140 |
Sex (males/females), n (%) | 16 (76.2)/5 (23.8) | 15 (71.4)/6 (28.6) | 0.726 |
Duration of diabetes (years) | 3.9 ± 3.7 | 3.0 ± 2.7 | 0.403 |
Body weight (kg) | 80.3 ± 19.0 | 84.4 ± 16.1 | 0.469 |
Body mass index (kg/m2) | 28.6 ± 4.8 | 30.0 ± 5.0 | 0.398 |
HbA1c (%) | 7.1 ± 0.8 | 7.0 ± 0.9 | 0.684 |
eGFR (mL/min/1.73 m2) | 86.5 ± 19.0 | 87.1 ± 14.4 | 0.907 |
Fasting plasma insulin (μU/mL) | 13.7 ± 7.1 | 14.4 ± 9.5 | 0.795 |
Free fatty acid (μEq/L) | 710.2 ± 164.2 | 689.8 ± 209.0 | 0.727 |
BNP (pg/mL) | 8.9 ± 5.8 | 13.5 ± 12.8 | 0.138 |
Pericardial fat (mm2) | 2310.1 ± 1065.1 | 2462.0 ± 947.7 | 0.628 |
Myocardial triglyceride content (%) | 5.9 ± 9.8 | 3.1 ± 3.1 | 0.220 |
Microvascular complications, n (%) | |||
 Diabetic retinopathy | 0 (0.0) | 0 (0.0) | – |
 Diabetic nephropathy | 1 (4.8) | 0 (0.0) | 1.000 |
 Diabetic neuropathy | 0 (0.0) | 0 (0.0) | – |
Macrovascular complications, n (%) | |||
 Cerebrovascular disease | 0 (0.0) | 0 (0.0) | – |
 Coronary disease | 0 (0.0) | 0 (0.0) | – |
 Peripheral arterial disease | 1 (4.8) | 0 (0.0) | 1.000 |
Anti-diabetic drugs, n (%) | |||
 α-Glucosidase inhibitors | 5 (23.8) | 5 (23.8) | 1.000 |
 Glinides | 4 (19.0) | 3 (14.3) | 1.000 |
 Sulfonylureas | 7 (33.3) | 7 (33.3) | 1.000 |
Antihypertensive drugs, n (%) | |||
 Diuretic drugs | 1 (4.8) | 2 (9.5) | 1.000 |
 Calcium channel blockers | 6 (28.6) | 3 (14.3) | 0.454 |
 Angiotensin-converting enzyme inhibitors | 0 (0.0) | 0 (0.0) | – |
 Angiotensin II receptor blockers | 7 (33.3) | 2 (9.5) | 0.130 |
 α-Blockers | 0 (0.0) | 0 (0.0) | – |
 β-blockers | 1 (4.8) | 0 (0.0) | 1.000 |